Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (191-200 of 362) with videos related to

Pageof 37
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|June 20, 2019
<sup>18</sup>F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancerMario Jreige, Igor Letovanec, Kariman Chaba, et al.
Psycho-Oncology|November 22, 2025
The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled TrialMarie-Estelle Gaignard, Dominica Martin, Jelena Stanic, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
Journal for Immunotherapy of Cancer|October 23, 2021
<sup>68</sup>Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditisSarah Boughdad, Sofiya Latifyan, Craig Fenwick, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2024
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastasesSolange Peters, José Trigo, Benjamin Besse, et al.
Cancer Treatment and Research Communications|December 21, 2024
Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosisLouis-Emmanuel Chriqui, Etienne Abdelnour-Berchtold, Edoardo Zanfrini, et al.
Contemporary Oncology (Poznan, Poland)|February 26, 2024
High-dose alectinib for <i>RET</i> fusion-positive non-small cell lung cancer in the Blood First Assay Screening TrialRafal Dziadziuszko, Nir Peled, Tony Mok, et al.
Expert Review of Anticancer Therapy|December 11, 2024
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancerManuel Dómine Gómez, Vivek Subbiah, Solange Peters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC StudyHan Si, Michael Kuziora, Katie J Quinn, et al.
Revue Medicale Suisse|April 8, 2021
[Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]Jeremy Jankovic, André Manuel Da Silva Lopes, Aurélie Morez, et al.
Pageof 37

Showing results (191-200 of 362) with videos related to

Sort By:
Pageof 37
European Journal of Nuclear Medicine and Molecular Imaging|June 20, 2019
<sup>18</sup>F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancerMario Jreige, Igor Letovanec, Kariman Chaba, et al.
Psycho-Oncology|November 22, 2025
The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled TrialMarie-Estelle Gaignard, Dominica Martin, Jelena Stanic, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
Journal for Immunotherapy of Cancer|October 23, 2021
<sup>68</sup>Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditisSarah Boughdad, Sofiya Latifyan, Craig Fenwick, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2024
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastasesSolange Peters, José Trigo, Benjamin Besse, et al.
Cancer Treatment and Research Communications|December 21, 2024
Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosisLouis-Emmanuel Chriqui, Etienne Abdelnour-Berchtold, Edoardo Zanfrini, et al.
Contemporary Oncology (Poznan, Poland)|February 26, 2024
High-dose alectinib for <i>RET</i> fusion-positive non-small cell lung cancer in the Blood First Assay Screening TrialRafal Dziadziuszko, Nir Peled, Tony Mok, et al.
Expert Review of Anticancer Therapy|December 11, 2024
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancerManuel Dómine Gómez, Vivek Subbiah, Solange Peters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC StudyHan Si, Michael Kuziora, Katie J Quinn, et al.
Revue Medicale Suisse|April 8, 2021
[Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]Jeremy Jankovic, André Manuel Da Silva Lopes, Aurélie Morez, et al.
Pageof 37